Today: 9 June 2026
Zurich’s £7.7bn Beazley takeover bid goes public after board rebuff
19 January 2026
2 mins read

Zurich’s £7.7bn Beazley takeover bid goes public after board rebuff

London, 19 January 2026, 16:17 GMT

  • Zurich has raised its cash offer for Beazley to 1,280p a share, following the rejection of an earlier 1,230p bid
  • Beazley shares surged over 40% in London after the bid was announced publicly
  • Zurich has until Feb. 16 under UK takeover rules to either finalize the offer or pull out

Zurich Insurance Group revealed on Monday an upgraded all-cash bid for UK specialty insurer Beazley, offering 1,280 pence per share. The deal values Beazley at roughly £7.67 billion ($10.3 billion). Following the announcement, Beazley’s shares jumped over 40% in London.

The move spotlights a niche in insurance: specialty coverage, where insurers tackle more specific, complex risks and aim to price them precisely. At the heart of this sector is Lloyd’s of London, serving as a marketplace where syndicates underwrite everything from cyber attacks to shipping and property risks.

Zurich said acquiring Beazley would add Beazley’s Lloyd’s footprint to its specialty lines push and strengthen Zurich’s UK presence. It highlighted its newly established Global Specialty Unit, noting the merged company would generate roughly $15 billion in gross written premiums — premiums before reinsurance and deductions.

Zurich put forward a 1,230 pence per share cash offer on Jan. 4, but it was rejected, the company confirmed. Insurance Times described the bid as a significant move for the London-listed insurer.

Zurich’s updated 1,280p bid represents a 56% premium over Beazley’s closing price on Jan. 16 and a 27% premium to the median sell-side analyst target it referenced. Under UK takeover rules, Zurich must announce a firm offer or withdraw by 5 p.m. London time on Feb. 16.

Zurich plans to finance the deal with a mix of existing cash and new debt, topping up the rest through an equity placing—issuing fresh shares to investors. The company also confirmed the transaction will boost its 2027 financial targets.

Zurich CEO Mario Greco told the Financial Times this marks the group’s fifth attempt in about a year and that “it was time to go public” and hear from shareholders directly. Jefferies analyst Philip Kett described the bid as offering “fair value” but noted the roughly two-times price-to-book multiple—a comparison of the offer to the company’s net asset value—was “perhaps not as high as it could be.” The FT also reported Zurich is working with advisors Goldman Sachs, Lazard, and UBS. https://www.ft.com/content/dab5a3b3-787c-4…

Beazley, established in 1986, has made its mark in specialty underwriting, covering areas like cyber and fine art, according to The Times. Zurich, with a workforce exceeding 63,000, said the deal would form a larger specialty unit based in the UK.

Beazley has yet to respond to the recent approach. Zurich, however, described the move as a strategy to accelerate growth in specialty lines instead of expanding the platform organically.

The road ahead isn’t straightforward. Beazley’s board has yet to back the offer, and Zurich’s strategy depends partly on raising equity—something that gets tricky if markets falter or investors hesitate over the price. Regulators and Lloyd’s oversight loom as well. As Beazley’s shares hover near the offer price, the market begins to factor in the risk of the deal falling through—or the possibility of a better bid emerging.

The bid sparked renewed focus on other specialty firms listed in London, as investors looked for clues on sector valuations. A competing offer would swiftly challenge Zurich’s determination.

The next key date is mid-February. Should Zurich commit firmly by that point, attention will turn to Beazley’s board—whether they respond, the terms tied to any recommendation, and how Zurich’s funding plan stands up to close examination.

Stock Market Today

  • Lean Hog Futures Drop as USDA Reports Mixed Prices and Increased Slaughter
    June 9, 2026, 9:30 AM EDT. Lean hog futures fell 310 cents to $1.52 at midday Monday. The USDA's national base hog price rose $1.83 to $96.01, while the CME Lean Hog Index edged up 9 cents to $92.60 on June 4. The USDA pork carcass cutout value decreased 42 cents to $100.76 per hundredweight, with loin, butt, and picnic cuts lower. Federally inspected hog slaughter increased by 75,193 head year-over-year to 2.428 million last week. The CFTC Commitment of Traders report showed managed money held a net short position of 6,551 contracts in lean hog futures and options, the first in nearly two years, flipping 19,536 contracts to the short side. Nearby hog futures contracts declined across June, July, and August delivery months.

Latest articles

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Tencent stock falls to HK$610 — what investors watch next after China growth data
Previous Story

Tencent stock falls to HK$610 — what investors watch next after China growth data

Silver price rockets to record near $94 as Trump tariff threat jolts markets
Next Story

Silver price rockets to record near $94 as Trump tariff threat jolts markets

Go toTop